BioLineRX announces annual shareholder meeting
BLRX•Annual meeting set for Sept. 23, 2026
BioLineRX will hold its annual general meeting of shareholders on Sept. 23, 2026.
Shareholders will vote on the re-election of three Class III directors to terms running to the 2029 annual meeting.
Other items include an increase in authorized share capital with a related amendment to the articles of association.
Equity-based compensation grants are also up for approval, including awards for CEO Philip Serlin and option grants for certain directors.
The meeting will also consider reappointing Kesselman & Kesselman (PwC member firm) as independent auditor for the year ending Dec. 31, 2026.
